NASDAQ:EXEL - Exelixis Stock Price, Price Target & More

$20.83 +0.43 (+2.11 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$20.40
Today's Range$20.11 - $21.2797
52-Week Range$18.03 - $32.50
Volume2.67 million shs
Average Volume3.08 million shs
Market Capitalization$6.15 billion
P/E Ratio40.84
Dividend YieldN/A
Beta2.1

About Exelixis (NASDAQ:EXEL)

Exelixis logoExelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.21%
Quick Ratio4.15%

Price-To-Earnings

Trailing P/E Ratio40.84
Forward P/E Ratio35.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$452.48 million
Price / Sales13.66
Cash Flow$0.5493 per share
Price / Cash37.92
Book Value$0.96 per share
Price / Book21.70

Profitability

EPS (Most Recent Fiscal Year)$0.51
Net Income$154.22 million
Net Margins34.08%
Return on Equity81.05%
Return on Assets27.10%

Miscellaneous

Employees372
Outstanding Shares296,660,000

How to Become a New Pot Stock Millionaire

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis (NASDAQ:EXEL) posted its earnings results on Monday, February, 26th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.12. The biotechnology company had revenue of $120.10 million for the quarter, compared to analyst estimates of $120.25 million. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. Exelixis's revenue was up 54.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.12 EPS. View Exelixis' Earnings History.

When is Exelixis' next earnings date?

Exelixis is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Exelixis.

What price target have analysts set for EXEL?

12 brokerages have issued 1 year price targets for Exelixis' stock. Their forecasts range from $28.00 to $40.00. On average, they anticipate Exelixis' stock price to reach $34.00 in the next twelve months. View Analyst Ratings for Exelixis.

What are Wall Street analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:
  • 1. Cann analysts commented, "We have not modeled any impact from international sales in the front line RCC setting; therefore, if approved by the EMA, this could provide upside to our Cabometyx outlook. Additionally, we anticipate that under the terms of the Ipsen collaboration, Exelixis will receive a milestone payment in Q1 2018 that will exceed our estimate by approximately $30 million, but the full-year 2018 will remain unchanged, resulting from the timing of this opinion being earlier in 2018 than we had anticipated." (3/20/2018)
  • 2. According to Zacks Investment Research, "Exelixis put up a strong performance in 2017 driven by gain in market share for Cabometyx. Sales are expected to get a further boost as the company will launch the drug for first-line RCC which will increases the eligible patient population for Caobometyx in the United States. A potential label expansion for advanced HCC will further boost the growth prospects. Shares of the company have outperformed the industry in the past one year. However, Exelixis is heavily dependent on Cabometyx for growth. Competition should stiffen up in 2018 as the FDA accepted Bristol-Myers’ supplemental Biologics License Application for priority review of Opdivo plus Yervoy to treat intermediate- and poor-risk patients with advanced RCC with an action date in Apr 2018. Moreover, there has been a slowdown in demand of Cabometyx in recent times and hence the company might find it tough to gain further market share." (3/19/2018)

Are investors shorting Exelixis?

Exelixis saw a decline in short interest during the month of March. As of March 15th, there was short interest totalling 12,605,994 shares, a decline of 10.2% from the February 28th total of 14,036,854 shares. Based on an average daily volume of 3,051,228 shares, the days-to-cover ratio is presently 4.1 days. Approximately 4.4% of the company's shares are short sold.

Who are some of Exelixis' key competitors?

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:
  • Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 70)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 57)
  • Mr. Christopher J. Senner, Exec. VP, CFO & Principal Accounting Officer (Age 50)
  • Dr. Peter Lamb Ph.D., Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 57)
  • Mr. Jeffrey J. Hessekiel J.D., Exec. VP, Gen. Counsel & Sec. (Age 49)

Has Exelixis been receiving favorable news coverage?

News headlines about EXEL stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exelixis earned a daily sentiment score of 0.05 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 47.60 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $20.83.

How big of a company is Exelixis?

Exelixis has a market capitalization of $6.15 billion and generates $452.48 million in revenue each year. The biotechnology company earns $154.22 million in net income (profit) each year or $0.51 on an earnings per share basis. Exelixis employs 372 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]


MarketBeat Community Rating for Exelixis (EXEL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  315 (Vote Outperform)
Underperform Votes:  251 (Vote Underperform)
Total Votes:  566
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Exelixis (NASDAQ:EXEL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Exelixis in the last 12 months. Their average twelve-month price target is $34.00, suggesting that the stock has a possible upside of 63.23%. The high price target for EXEL is $40.00 and the low price target for EXEL is $28.00. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.502.50
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $34.00$34.00$31.7143$31.2857
Price Target Upside: 63.23% upside38.72% upside16.81% upside7.81% upside

Exelixis (NASDAQ:EXEL) Consensus Price Target History

Price Target History for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ:EXEL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2018William BlairReiterated RatingBuyLowView Rating Details
3/20/2018CannReiterated RatingBuy$40.00LowView Rating Details
2/27/2018Stifel NicolausBoost Price TargetHold -> Hold$29.00 -> $30.00HighView Rating Details
2/27/2018OppenheimerUpgradeMarket Perform -> Outperform$40.00HighView Rating Details
2/27/2018UBSUpgradeMarket Perform -> OutperformHighView Rating Details
12/21/2017SunTrust BanksReiterated RatingBuy$38.00HighView Rating Details
10/17/2017Needham & Company LLCBoost Price TargetBuy$30.00 -> $33.00N/AView Rating Details
10/17/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$33.00 -> $39.00N/AView Rating Details
10/16/2017Piper JaffrayReiterated RatingOverweightN/AView Rating Details
9/22/2017Leerink SwannDowngradeOutperform -> Market Perform$34.00 -> $28.00HighView Rating Details
8/10/2017CowenReiterated RatingOutperformMediumView Rating Details
8/3/2017Deutsche BankDowngradeBuy -> Hold$26.00 -> $29.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Exelixis (NASDAQ:EXEL) Earnings History and Estimates Chart

Earnings by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ:EXEL) Earnings Estimates

2018 EPS Consensus Estimate: $0.56
2019 EPS Consensus Estimate: $0.86
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.08$0.30$0.16
Q2 20184$0.08$0.18$0.12
Q3 20184$0.08$0.21$0.13
Q4 20184$0.09$0.26$0.16
Q1 20191$0.18$0.18$0.18
Q2 20191$0.20$0.20$0.20
Q3 20191$0.23$0.23$0.23
Q4 20191$0.25$0.25$0.25

Exelixis (NASDAQ EXEL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018$0.14N/AView Earnings Details
2/26/2018Q4 2017$0.12$0.12$120.25 million$120.10 millionViewListenView Earnings Details
11/1/2017Q3 2017$0.08$0.26$104.91 million$152.50 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.04$0.06$85.27 million$99.01 millionViewListenView Earnings Details
5/1/2017Q1 2017($0.0090)$0.05$65.23 million$80.90 millionViewListenView Earnings Details
2/27/2017Q416($0.01)$0.12$64.88 million$77.58 millionViewListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
2/8/2012Q4 2011($0.13)$0.37ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.06)($0.08)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.17)($0.12)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.31)($0.25)ViewN/AView Earnings Details
3/9/2010Q4 2009($0.27)($0.25)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.33)($0.22)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.41)($0.33)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.31)($0.36)ViewN/AView Earnings Details
3/4/2009Q4 2008($0.35)($0.36)ViewN/AView Earnings Details
10/27/2008Q3 2008($0.41)($0.39)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.39)($0.43)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.37)($0.39)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.28)($0.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Exelixis (NASDAQ:EXEL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Exelixis (NASDAQ EXEL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 80.28%
Insider Trading History for Exelixis (NASDAQ:EXEL)
Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ EXEL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Alan M GarberDirectorSell15,000$20.25$303,750.0076,329View SEC Filing  
4/11/2018Michael MorrisseyInsiderSell90,000$20.78$1,870,200.00View SEC Filing  
3/6/2018Vincent T. MarchesiDirectorSell15,000$24.73$370,950.00View SEC Filing  
3/2/2018Lance WillseyDirectorSell30,000$23.91$717,300.00483,273View SEC Filing  
2/28/2018George PosteDirectorSell15,000$26.26$393,900.00View SEC Filing  
2/28/2018Patrick J. HaleyVPSell45,029$27.13$1,221,636.77View SEC Filing  
1/9/2018Alan M GarberDirectorSell15,000$30.30$454,500.0064,829View SEC Filing  
9/28/2017Gisela SchwabInsiderSell100,000$23.79$2,379,000.00View SEC Filing  
9/28/2017Jeffrey HessekielEVPSell27,302$24.28$662,892.56View SEC Filing  
9/22/2017Stelios PapadopoulosDirectorSell10,000$25.40$254,000.00View SEC Filing  
9/19/2017Stelios PapadopoulosDirectorSell200,000$27.68$5,536,000.00View SEC Filing  
9/18/2017Stelios PapadopoulosDirectorSell72,210$27.76$2,004,549.60View SEC Filing  
9/14/2017Michael MorrisseyInsiderSell300,000$26.90$8,070,000.00View SEC Filing  
9/14/2017Patrick J. HaleyVPSell60,640$27.21$1,650,014.40View SEC Filing  
9/13/2017Lance WillseyDirectorSell100,000$26.88$2,688,000.00518,273View SEC Filing  
9/12/2017Christopher J. SennerCFOSell100,000$26.79$2,679,000.00View SEC Filing  
5/30/2017Patrick J. HaleyInsiderSell5,000$18.46$92,300.00View SEC Filing  
5/15/2017Carl B FeldbaumDirectorSell32,988$21.58$711,881.0452,721View SEC Filing  
5/10/2017Michael MorrisseyInsiderSell211,300$21.87$4,621,131.00View SEC Filing  
5/9/2017Michael MorrisseyCEOSell100,000$21.69$2,169,000.00View SEC Filing  
5/8/2017Michael MorrisseyCEOSell11,300$21.81$246,453.00View SEC Filing  
5/5/2017Michael MorrisseyInsiderSell259,149$22.24$5,763,473.76View SEC Filing  
5/1/2017Gisela SchwabCMOSell89,910$23.01$2,068,829.10View SEC Filing  
4/3/2017Vincent T MarchesiDirectorSell10,000$21.30$213,000.00130,070View SEC Filing  
3/31/2017Jack L WyszomierskiDirectorSell5,150$21.57$111,085.5078,110View SEC Filing  
3/27/2017Jeffrey HessekielEVPSell6,884$21.02$144,701.68View SEC Filing  
3/22/2017Jeffrey HessekielEVPSell23,787$20.54$488,584.98View SEC Filing  
3/20/2017Stelios PapadopoulosDirectorSell10,000$21.66$216,600.001,238,471View SEC Filing  
3/13/2017Charles CohenDirectorSell10,000$21.82$218,200.00238,180View SEC Filing  
3/10/2017Vincent T MarchesiDirectorSell40,000$21.98$879,200.00160,070View SEC Filing  
3/6/2017Michael MorrisseyInsiderSell200,000$22.72$4,544,000.00View SEC Filing  
3/3/2017Christopher J. SennerCFOSell11,000$22.80$250,800.00View SEC Filing  
3/2/2017George PosteDirectorSell76,250$22.53$1,717,912.5086,405View SEC Filing  
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00174,354View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00548,273View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00548,273View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00494,975View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.2036,473View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.0036,473View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.8436,473View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00333,700View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Exelixis (NASDAQ EXEL) News Headlines

Source:
DateHeadline
Bristol-Myers And Exelixis Poise For Battle In Kidney Cancer - Who Will Emerge The Victor?Bristol-Myers And Exelixis Poise For Battle In Kidney Cancer - Who Will Emerge The Victor?
seekingalpha.com - April 24 at 3:10 PM
Exelixis (EXEL) Expected to Announce Earnings of $0.15 Per ShareExelixis (EXEL) Expected to Announce Earnings of $0.15 Per Share
www.americanbankingnews.com - April 24 at 1:14 AM
Exelixis (EXEL) to Release Quarterly Earnings on MondayExelixis (EXEL) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 23 at 7:14 AM
Exelixis (EXEL) Director Sells $303,750.00 in StockExelixis (EXEL) Director Sells $303,750.00 in Stock
www.americanbankingnews.com - April 18 at 10:11 PM
SunTrust Banks Analysts Raise Earnings Estimates for Exelixis (EXEL)SunTrust Banks Analysts Raise Earnings Estimates for Exelixis (EXEL)
www.americanbankingnews.com - April 18 at 7:58 AM
Equities Analysts Offer Predictions for Exelixis Q1 2018 Earnings (EXEL)Equities Analysts Offer Predictions for Exelixis' Q1 2018 Earnings (EXEL)
www.americanbankingnews.com - April 18 at 7:58 AM
Exelixis (EXEL) Forecasted to Post Q4 2018 Earnings of $0.14 Per ShareExelixis (EXEL) Forecasted to Post Q4 2018 Earnings of $0.14 Per Share
www.americanbankingnews.com - April 17 at 6:46 AM
Insider Selling: Exelixis (EXEL) Insider Sells 90,000 Shares of StockInsider Selling: Exelixis (EXEL) Insider Sells 90,000 Shares of Stock
www.americanbankingnews.com - April 13 at 10:10 PM
Exelixis (EXEL) Stock Rating Reaffirmed by Stifel NicolausExelixis (EXEL) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - April 13 at 9:27 PM
Exelixis (EXEL) Earns "Buy" Rating from Piper JaffrayExelixis (EXEL) Earns "Buy" Rating from Piper Jaffray
www.americanbankingnews.com - April 13 at 3:51 PM
BRIEF-Exelixis Says CEO Michael Morrisseys FY 2017 Total Compensation Was $9.4 Mln VS $6.3 MlnBRIEF-Exelixis Says CEO Michael Morrissey's FY 2017 Total Compensation Was $9.4 Mln VS $6.3 Mln
www.reuters.com - April 13 at 5:04 AM
Form DEF 14A EXELIXIS, INC. For: May 23Form DEF 14A EXELIXIS, INC. For: May 23
www.streetinsider.com - April 13 at 5:04 AM
Why Exelixis Stock Broke Down in MarchWhy Exelixis' Stock Broke Down in March
www.fool.com - April 12 at 3:09 PM
Why Exelixis' Stock Broke Down in MarchWhy Exelixis' Stock Broke Down in March
finance.yahoo.com - April 12 at 3:09 PM
Exelixis (EXEL) Earns "Buy" Rating from William BlairExelixis (EXEL) Earns "Buy" Rating from William Blair
www.americanbankingnews.com - April 12 at 10:27 AM
Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018
finance.yahoo.com - April 12 at 5:15 AM
Exelixis (EXEL) Upgraded to "B-" by TheStreetExelixis (EXEL) Upgraded to "B-" by TheStreet
www.americanbankingnews.com - April 12 at 12:28 AM
Exelixis (EXEL) Receives "Outperform" Rating from CowenExelixis (EXEL) Receives "Outperform" Rating from Cowen
www.americanbankingnews.com - April 11 at 5:01 PM
Exelixis (EXEL) in Focus: Stock Moves 7.7% HigherExelixis (EXEL) in Focus: Stock Moves 7.7% Higher
finance.yahoo.com - April 11 at 3:14 PM
Investors Purchase High Volume of Call Options on Exelixis (EXEL)Investors Purchase High Volume of Call Options on Exelixis (EXEL)
www.americanbankingnews.com - April 11 at 7:51 AM
Investors Purchase High Volume of Put Options on Exelixis (EXEL)Investors Purchase High Volume of Put Options on Exelixis (EXEL)
www.americanbankingnews.com - April 11 at 7:04 AM
Exelixis (EXEL) Rating Lowered to Buy at BidaskClubExelixis (EXEL) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 10 at 4:26 PM
Exelixis Rebounds As Analyst Urges Investors To Buy Monday's DipExelixis Rebounds As Analyst Urges Investors To Buy Monday's Dip
finance.yahoo.com - April 10 at 3:01 PM
Form 4 EXELIXIS, INC. For: Apr 05 Filed by: Freire Maria CForm 4 EXELIXIS, INC. For: Apr 05 Filed by: Freire Maria C
www.streetinsider.com - April 10 at 5:04 AM
Exelixis Elects Dr. Maria Freire to Its Board of DirectorsExelixis Elects Dr. Maria Freire to Its Board of Directors
finance.yahoo.com - April 10 at 5:04 AM
Zacks: Brokerages Anticipate Exelixis (EXEL) Will Post Quarterly Sales of $132.69 MillionZacks: Brokerages Anticipate Exelixis (EXEL) Will Post Quarterly Sales of $132.69 Million
www.americanbankingnews.com - April 9 at 4:27 AM
Exelixis (EXEL) Receives Average Rating of "Hold" from AnalystsExelixis (EXEL) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 8 at 5:11 AM
Exelixis (EXEL) Upgraded to Buy by Zacks Investment ResearchExelixis (EXEL) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM
Exelixis (EXEL) Receives Hold Rating from Stifel NicolausExelixis (EXEL) Receives Hold Rating from Stifel Nicolaus
www.americanbankingnews.com - April 7 at 11:39 AM
Exelixis (EXEL) Expected to Post Earnings of $0.12 Per ShareExelixis (EXEL) Expected to Post Earnings of $0.12 Per Share
www.americanbankingnews.com - April 7 at 3:30 AM
Moving Average Crossover Alert: Exelixis, Inc. (EXEL)Moving Average Crossover Alert: Exelixis, Inc. (EXEL)
finance.yahoo.com - April 6 at 3:14 PM
Today’s Research Reports on Trending Tickers: Exelixis and Galectin TherapeuticsToday’s Research Reports on Trending Tickers: Exelixis and Galectin Therapeutics
finance.yahoo.com - April 5 at 9:26 AM
Weakness Seen in Exelixis (EXEL) Estimates: Should You Stay Away?Weakness Seen in Exelixis (EXEL) Estimates: Should You Stay Away?
www.nasdaq.com - April 4 at 4:43 PM
BidaskClub Lowers Exelixis (EXEL) to Strong SellBidaskClub Lowers Exelixis (EXEL) to Strong Sell
www.americanbankingnews.com - April 4 at 9:31 AM
Why Spark Therapeutics Stock Rose in the Week Ended March 29Why Spark Therapeutics Stock Rose in the Week Ended March 29
finance.yahoo.com - April 3 at 3:08 PM
Today’s Research Reports on Trending Tickers: Exelixis and Sarepta TherapeuticsToday’s Research Reports on Trending Tickers: Exelixis and Sarepta Therapeutics
finance.yahoo.com - March 29 at 3:08 PM
Short Interest in Exelixis (EXEL) Decreases By 10.2%Short Interest in Exelixis (EXEL) Decreases By 10.2%
www.americanbankingnews.com - March 29 at 3:32 AM
Why Is Exelixis (EXEL) Down 17.2% Since Its Last Earnings Report?Why Is Exelixis (EXEL) Down 17.2% Since Its Last Earnings Report?
finance.yahoo.com - March 28 at 3:03 PM
Exelixis Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYXExelixis' Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX
www.businesswire.com - March 28 at 5:43 AM
Exelixis Cabometyx Gets Positive CHMP Opinion in EuropeExelixis Cabometyx Gets Positive CHMP Opinion in Europe
finance.yahoo.com - March 26 at 3:01 PM
(cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma(cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
www.businesswire.com - March 25 at 9:39 AM
Exelixis (EXEL) Rating Increased to Outperform at UBSExelixis (EXEL) Rating Increased to Outperform at UBS
www.americanbankingnews.com - March 24 at 10:39 PM
Exelixis (EXEL) Lifted to Outperform at CannExelixis (EXEL) Lifted to Outperform at Cann
www.americanbankingnews.com - March 24 at 10:02 PM
Exelixis (EXEL) Downgraded to Hold at BidaskClubExelixis (EXEL) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 24 at 4:30 PM
RSI Alert: Exelixis (EXEL) Now Oversold - NasdaqRSI Alert: Exelixis (EXEL) Now Oversold - Nasdaq
www.nasdaq.com - March 24 at 8:02 AM
Exelixis (EXEL) Reports Positive CHMP Opinion for CABOMETYX ... - StreetInsider.comExelixis (EXEL) Reports Positive CHMP Opinion for CABOMETYX ... - StreetInsider.com
www.streetinsider.com - March 24 at 8:02 AM
European advisory group backs Exelixis Cabometyx for first-line kidney cancerEuropean advisory group back's Exelixis' Cabometyx for first-line kidney cancer
seekingalpha.com - March 23 at 6:31 PM
BRIEF-Exelixis Partner Ipsen Announces Positive CHMP Opinion For CabometyxBRIEF-Exelixis' Partner Ipsen Announces Positive CHMP Opinion For Cabometyx
www.reuters.com - March 23 at 6:31 PM
Exelixis (EXEL) Reports Positive CHMP Opinion for CABOMETYX (cabozantinib)Exelixis (EXEL) Reports Positive CHMP Opinion for CABOMETYX (cabozantinib)
www.streetinsider.com - March 23 at 6:31 PM
Exelixis (EXEL) Expected to Post Quarterly Sales of $129.22 MillionExelixis (EXEL) Expected to Post Quarterly Sales of $129.22 Million
www.americanbankingnews.com - March 23 at 9:08 AM

SEC Filings

Exelixis (NASDAQ:EXEL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Exelixis (NASDAQ:EXEL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Exelixis (NASDAQ EXEL) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.